CTLA4 and cancer: Amongst them was the extraordinarily successful immune checkpoint therapy (ICP) with antibodies targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA4) or programmed death 1/ligand 1(PD1)/(PDL1), which overcame immune suppression and induced sustained regression of disease in a subset of patients with cancer [6].